Targeting delivery of lipocalin 2-engineered mesenchymal stem cells to colon cancer in order to inhibit liver metastasis in nude mice

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Mozhgan Dehghan HaratiMehryar Habibi Roudkenar

Abstract

One of the major obstacles in cancer therapy is the lack of anticancer agent specificity to tumor tissues. The strategy of cell-based therapy is a promising therapeutic option for cancer treatment. The specific tumor-oriented migration of mesenchymal stem cells (MSCs) makes them a useful vehicle to deliver anticancer agents. In this study, we genetically manipulated bone marrow-derived mesenchymal stem cells with their lipocalin 2 (Lcn2) in order to inhibit liver metastasis of colon cancer in nude mice. Lcn2 was successfully overexpressed in transfected MSCs. The PCR results of SRY gene confirmed the presence of MSCs in cancer liver tissue. This study showed that Lcn2-engineered MSCs (MSC-Lcn2) not only inhibited liver metastasis of colon cancer but also downregulated the expression of vascular endothelial growth factor (VEGF) in the liver. Overall, MSCs by innate tropism toward cancer cells can deliver the therapeutic agent, Lcn2, and inhibit cancer metastasis. Hence, it could be a new modality for efficient targeted delivery of anticancer agent to liver metastasis.

References

Jun 5, 1999·Cellular and Molecular Life Sciences : CMLS·G J MaestroniP Galli
Dec 29, 2005·International Journal of Cancer. Journal International Du Cancer·Ho-Jeong LeeJang-Seong Kim
Jun 22, 2006·Journal of Surgical Oncology·Nigel C BirdAli W Majeed
Nov 23, 2006·Molecular Cancer Research : MCR·Shivalingappa VenkateshaVikas P Sukhatme
Apr 25, 2007·Journal of Nanoscience and Nanotechnology·Shinji MoritakeMitsutoshi Setou
Jul 10, 2007·Cancer Research·Lucia KucerovaCestmir Altaner
Apr 23, 2008·Cancer·Kevin D SteinMichael A Andrykowski
May 14, 2009·Cancer Research·Michael R LoebingerSam M Janes
May 25, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yu-Lan HuJian-Qing Gao
Mar 15, 2011·Cancer Letters·Long-Jun DaiGarth L Warnock
Jun 15, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Seung Ah ChoiSeung-Ki Kim
Dec 20, 2011·World Journal of Stem Cells·Xu-Yong SunLong-Jun Dai
Mar 1, 2012·Cell Stress & Chaperones·Mohammad MohammadzadehMehryar Habibi Roudkenar
Sep 18, 2012·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Jiang YangMarsha A Moses
Sep 16, 2014·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayFreddie Bray
Apr 5, 2013·Biomaterials Science·Maroof AdilEfrosini Kokkoli

❮ Previous
Next ❯

Citations

Dec 3, 2016·Future Oncology·Maliha KhanAmanda L Olson
Sep 14, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Nuo JiBo-Jian Jiang
Apr 27, 2019·Reviews in the Neurosciences·Ahmad MehdipourAbbas Ebrahimi-Kalan
Dec 12, 2018·Canadian Journal of Gastroenterology & Hepatology·Shan WangJinzhou Zhang
Nov 17, 2020·Frontiers in Cell and Developmental Biology·Jeanne Adiwinata PawitanDelvac Oceandy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.